JP2002520316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002520316A5 JP2002520316A5 JP2000559090A JP2000559090A JP2002520316A5 JP 2002520316 A5 JP2002520316 A5 JP 2002520316A5 JP 2000559090 A JP2000559090 A JP 2000559090A JP 2000559090 A JP2000559090 A JP 2000559090A JP 2002520316 A5 JP2002520316 A5 JP 2002520316A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- compound
- alkyl
- alkylcarbamoyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 17
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- -1 2-oxo-tetrahydro-1 (2H) -pyrimidinyl Chemical group 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 125000001475 halogen functional group Chemical group 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 125000005236 alkanoylamino group Chemical group 0.000 description 3
- 125000005281 alkyl ureido group Chemical group 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 description 1
- SJHZTGDJTIZMSK-KPRDSAADSA-N 3-cyano-n-[(2s)-2-(3,4-dichlorophenyl)-4-[4-[2-[(s)-methylsulfinyl]phenyl]piperidin-1-yl]butyl]-n-methylnaphthalene-1-carboxamide Chemical compound C([C@H](CN(C)C(=O)C=1C2=CC=CC=C2C=C(C=1)C#N)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1C1=CC=CC=C1[S@](C)=O SJHZTGDJTIZMSK-KPRDSAADSA-N 0.000 description 1
- VHQVJYKYAGBACO-UDKJZQBVSA-N 3-cyano-n-[(2s)-2-(3,4-dichlorophenyl)-4-[4-[4-methoxy-2-[(s)-methylsulfinyl]phenyl]piperidin-1-yl]butyl]-n-methylnaphthalene-1-carboxamide Chemical compound C[S@](=O)C1=CC(OC)=CC=C1C1CCN(CC[C@H](CN(C)C(=O)C=2C3=CC=CC=C3C=C(C=2)C#N)C=2C=C(Cl)C(Cl)=CC=2)CC1 VHQVJYKYAGBACO-UDKJZQBVSA-N 0.000 description 1
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 description 1
- 0 Cc1c(C(N(C)C[C@@](CCN(CC2)CCC2c2ccc(*)cc2[S@@](C)=O)c(cc2)cc(Cl)c2Cl)=O)c(ccc(*)c2)c2c(*)c1* Chemical compound Cc1c(C(N(C)C[C@@](CCN(CC2)CCC2c2ccc(*)cc2[S@@](C)=O)c(cc2)cc(Cl)c2Cl)=O)c(ccc(*)c2)c2c(*)c1* 0.000 description 1
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 description 1
- 102000007124 Tachykinin Receptors Human genes 0.000 description 1
- 108010072901 Tachykinin Receptors Proteins 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9814886.9 | 1998-07-10 | ||
| GBGB9814886.9A GB9814886D0 (en) | 1998-07-10 | 1998-07-10 | N-Substituted naphthalenecarboxamides |
| GB9821703.7 | 1998-10-07 | ||
| GBGB9821703.7A GB9821703D0 (en) | 1998-10-07 | 1998-10-07 | Compounds |
| GBGB9821699.7A GB9821699D0 (en) | 1998-10-07 | 1998-10-07 | Compounds |
| GB9821699.7 | 1998-10-07 | ||
| GBGB9909840.2A GB9909840D0 (en) | 1999-04-30 | 1999-04-30 | Compounds |
| GB9909840.2 | 1999-04-30 | ||
| PCT/GB1999/002178 WO2000002859A1 (en) | 1998-07-10 | 1999-07-07 | N-substituted naphthalene carboxamides as neurokinin-receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002520316A JP2002520316A (ja) | 2002-07-09 |
| JP2002520316A5 true JP2002520316A5 (enExample) | 2006-08-03 |
Family
ID=27451806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000559090A Pending JP2002520316A (ja) | 1998-07-10 | 1999-07-07 | ニューロキニン受容体アンタゴニストとしてのｎ−置換ナフタレンカルボキサミド |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6365602B1 (enExample) |
| EP (1) | EP1097137A1 (enExample) |
| JP (1) | JP2002520316A (enExample) |
| KR (1) | KR20010083100A (enExample) |
| CN (1) | CN1309638A (enExample) |
| AR (1) | AR019365A1 (enExample) |
| AU (1) | AU4637899A (enExample) |
| BR (1) | BR9912013A (enExample) |
| CA (1) | CA2336806A1 (enExample) |
| ID (1) | ID24739A (enExample) |
| IL (1) | IL140770A0 (enExample) |
| NO (1) | NO20010151L (enExample) |
| WO (1) | WO2000002859A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001014336A1 (en) * | 1999-08-20 | 2001-03-01 | Nippon Kayaku Kabushiki Kaisha | Benzene derivatives substituted by aromatic ring and process for producing the same |
| US6271418B1 (en) | 2000-02-22 | 2001-08-07 | Nippon Kayaku Co., Ltd. | Process for preparing (hetero) aromatic substituted benzene derivatives |
| US6903092B2 (en) | 2000-04-06 | 2005-06-07 | Peter Bernstein | Naphthamide neurokinin antagonists for use as medicaments |
| ES2307605T3 (es) * | 2000-04-06 | 2008-12-01 | Astrazeneca Ab | Nuevos antagonistas de neuroquininas para su uso como medicamentos. |
| ATE308513T1 (de) * | 2000-04-06 | 2005-11-15 | Naphthamid-neurokinin antagonisten zur verwendung als medikamente | |
| US6846814B2 (en) | 2000-04-06 | 2005-01-25 | Astra Zeneca Ab | Neurokinin antagonists for use as medicaments |
| GB0015246D0 (en) * | 2000-06-22 | 2000-08-16 | Astrazeneca Ab | Method for the treatment of urinary incontinence |
| FR2813891B1 (fr) * | 2000-09-14 | 2005-01-14 | Immunotech Sa | Reactif multifonctionnel pour erythrocytes mettant en jeu des carbamates et applications |
| AU7622500A (en) * | 2000-09-29 | 2002-07-01 | Neurogen Corp | High affinity small molecule c5a receptor modulators |
| SE0004827D0 (sv) | 2000-12-22 | 2000-12-22 | Astrazeneca Ab | Therapeutic compounds |
| US6727264B1 (en) * | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
| BR0214295A (pt) * | 2001-11-19 | 2004-11-09 | Elan Pharm Inc | Composto, método para tratar um paciente que tem ou prevenir um paciente de adquirir uma doença ou condição, e, método para produzir um composto |
| ATE416162T1 (de) * | 2002-08-29 | 2008-12-15 | Astrazeneca Ab | Naphthamidderivate und deren verwendung |
| JP2006505461A (ja) * | 2002-11-05 | 2006-02-16 | アストラゼネカ・アクチエボラーグ | 錠止蓋を有する安全容器および蓋を錠止する方法 |
| EP1581495B1 (en) * | 2002-12-20 | 2007-04-18 | AstraZeneca AB | 4-aryl-4-(naphth-1-ylmethylamino)methyl-piperidine compounds and their use |
| TW200508221A (en) * | 2003-06-13 | 2005-03-01 | Astrazeneca Ab | New azetidine compounds |
| TW200524868A (en) * | 2003-07-31 | 2005-08-01 | Zeria Pharm Co Ltd | Benzylamine derivatives |
| SE0403005D0 (sv) * | 2004-12-09 | 2004-12-09 | Astrazeneca Ab | New use |
| CN101208327A (zh) * | 2005-06-23 | 2008-06-25 | 阿斯利康(瑞典)有限公司 | 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物 |
| CN101203511A (zh) * | 2005-06-23 | 2008-06-18 | 阿斯利康(瑞典)有限公司 | 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物 |
| AR056087A1 (es) * | 2005-09-29 | 2007-09-19 | Astrazeneca Ab | Derivados de azetidina como antagonistas de receptores de neuroquina nk |
| AR057828A1 (es) * | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
| US20070219214A1 (en) * | 2006-02-01 | 2007-09-20 | Solvay Pharmaceuticals Gmbh | Dual NK2/NK3-antagonists, pharmaceutical compositions comprising them, and processes for their preparation |
| CN101374811A (zh) * | 2006-02-01 | 2009-02-25 | 索尔瓦药物有限公司 | 新型双重nk2/nk3-拮抗剂、含它们的药物组合物、及其制备方法 |
| US8106208B2 (en) | 2006-05-18 | 2012-01-31 | Albireo Ab | Benzamide compounds that act as NK receptor antagonists |
| US8093268B2 (en) | 2007-01-24 | 2012-01-10 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) |
| SI2358676T1 (sl) * | 2008-11-14 | 2013-01-31 | Theravance, Inc. | Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine |
| CN116754685B (zh) * | 2023-07-07 | 2025-07-25 | 浙江新和成特种材料有限公司 | 一种利用高效液相色谱法测定pps浆料母液中甲硫醇钠含量的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI97540C (fi) * | 1989-11-06 | 1997-01-10 | Sanofi Sa | Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi |
| IL99320A (en) * | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical compositions containing them |
| JP2999829B2 (ja) * | 1990-12-31 | 2000-01-17 | 株式会社資生堂 | 皮膚外用剤 |
| FR2676054B1 (fr) | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2688219B1 (fr) * | 1992-03-03 | 1994-07-08 | Sanofi Elf | Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant. |
| GB9310713D0 (en) * | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Aryl substituted heterocycles |
| JPH06340526A (ja) * | 1993-06-02 | 1994-12-13 | Mitsui Toatsu Chem Inc | 置換１，４−ナフトキノン誘導体を有効成分として含有する神経成長因子産生、分泌誘発剤 |
| GB9617730D0 (en) * | 1996-08-23 | 1996-10-02 | Pfizer Ltd | Quarternary ammonium compounds |
-
1999
- 1999-07-07 CA CA002336806A patent/CA2336806A1/en not_active Abandoned
- 1999-07-07 US US09/743,335 patent/US6365602B1/en not_active Expired - Fee Related
- 1999-07-07 AU AU46378/99A patent/AU4637899A/en not_active Abandoned
- 1999-07-07 JP JP2000559090A patent/JP2002520316A/ja active Pending
- 1999-07-07 EP EP99929597A patent/EP1097137A1/en not_active Withdrawn
- 1999-07-07 CN CN99808501A patent/CN1309638A/zh active Pending
- 1999-07-07 BR BR9912013-5A patent/BR9912013A/pt not_active IP Right Cessation
- 1999-07-07 IL IL14077099A patent/IL140770A0/xx unknown
- 1999-07-07 KR KR1020017000376A patent/KR20010083100A/ko not_active Withdrawn
- 1999-07-07 WO PCT/GB1999/002178 patent/WO2000002859A1/en not_active Ceased
- 1999-07-08 AR ARP990103362A patent/AR019365A1/es unknown
- 1999-07-09 ID IDP990656D patent/ID24739A/id unknown
-
2001
- 2001-01-09 NO NO20010151A patent/NO20010151L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006518728A5 (enExample) | ||
| JP2005519083A5 (enExample) | ||
| RU2004134564A (ru) | Химические соединения | |
| JP2003509349A5 (enExample) | ||
| JP2005097323A5 (enExample) | ||
| JP2003525279A5 (enExample) | ||
| JP2005511698A5 (enExample) | ||
| CA2482004A1 (en) | Compounds having unique cb1 receptor binding selectivity and methods for their production and use | |
| JP2010514758A5 (enExample) | ||
| JP2005112864A5 (enExample) | ||
| EP2308828A3 (en) | CaSR antagonist | |
| JPH10279578A5 (enExample) | ||
| CA2398794A1 (en) | 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists | |
| JP2005511697A5 (enExample) | ||
| JP2005527542A5 (enExample) | ||
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| WO2006025070A3 (en) | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol | |
| JP2002527414A5 (enExample) | ||
| JP2002526410A5 (enExample) | ||
| CA2526991A1 (en) | Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor | |
| JP2004525183A5 (enExample) | ||
| RU2007116987A (ru) | Новые соединения | |
| JP2005516898A5 (enExample) | ||
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| JP2004525178A5 (enExample) |